Morning Briefing
Summaries of health policy coverage from major news organizations
Monkeypox Vaccine Gains European Approval; Enhertu Shows Promise Treating HER2-Low Breast Cancer
As the monkeypox outbreak rapidly spreads across the world, the World Health Organization (WHO) named the disease a public health emergency and Bavarian Nordic received an extended approval for its vaccine. (Becker, 7/25)
After winning a standing ovation at the recent American Society of Clinical Oncology meeting, Enhertu’s HER2-low breast cancer data are now getting the VIP treatment at the FDA. And the drug’s developers, AstraZeneca and Daiichi Sankyo, are targeting an ambitiously broad patient population. (Liu, 7/25)
The company is developing a series of platform technologies that aim to better write and deliver emerging genomic therapies — including larger payloads of targeted medicines than current delivery methods can handle. (Freeman, 7/25)
Over the last several weeks as Merck and Seagen have reportedly considered a merger, one of the key factors at play in determining the value of the Seattle biotech was impending data from a trial of its bladder cancer drug, Padcev. (Dunleavy, 7/26))
Most drugs developed to treat Alzheimer's disease have for years been ineffective in clinical trials. Researchers from Indiana University School of Medicine recently evaluated the efficacy of a failed clinical trial drug using their rigorous pipeline. (Indiana University School of Medicine, 7/25)
Controversy exists as to whether the threshold for blood pressure-lowering treatment should differ between people with and without type 2 diabetes. We aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiovascular events by type 2 diabetes status, as well as by baseline levels of systolic blood pressure. (Nazarzadeh, MSc, et al, 7/22)
